Kinetic and thermodynamic characterization of HIV‐1 protease inhibitors
- 25 February 2004
- journal article
- research article
- Published by Wiley in Journal of Molecular Recognition
- Vol. 17 (2) , 106-119
- https://doi.org/10.1002/jmr.655
Abstract
Interaction kinetic and thermodynamic analyses provide information beyond that obtained in general inhibition studies, and may contribute to the design of improved inhibitors and increased understanding of molecular interactions. Thus, a biosensor-based method was used to characterize the interactions between HIV-1 protease and seven inhibitors, revealing distinguishing kinetic and thermodynamic characteristics for the inhibitors. Lopinavir had fast association and the highest affinity of the tested compounds, and the interaction kinetics were less temperature-dependent as compared with the other inhibitors. Amprenavir, indinavir and ritonavir showed non-linear temperature dependencies of the kinetics. The free energy, enthalpy and entropy (ΔG, ΔH, ΔS) were determined, and the energetics of complex association (ΔGon, ΔHon, ΔSon) and dissociation (ΔGoff, ΔHoff, ΔSoff) were resolved. In general, the energetics for the studied inhibitors was in the same range, with the negative free energy change (ΔG < 0) due primarily to increased entropy (ΔS > 0). Thus, the driving force of the interaction was increased degrees of freedom in the system (entropy) rather than the formation of bonds between the enzyme and inhibitor (enthalpy). Although the ΔGon and ΔGoff were in the same range for all inhibitors, the enthalpy and entropy terms contributed differently to association and dissociation, distinguishing these phases energetically. Dissociation was accompanied by positive enthalpy (ΔHoff > 0) and negative entropy (ΔSoff < 0) changes, whereas association for all inhibitors except lopinavir had positive entropy changes (ΔSon > 0), demonstrating unique energetic characteristics for lopinavir. This study indicates that this type of data will be useful for the characterization of target–ligand interactions and the development of new inhibitors of HIV-1 protease. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
This publication has 40 references indexed in Scilit:
- Molecular Properties That Influence the Oral Bioavailability of Drug CandidatesJournal of Medicinal Chemistry, 2002
- The Binding Energetics of First- and Second-Generation HIV-1 Protease Inhibitors: Implications for Drug DesignArchives of Biochemistry and Biophysics, 2001
- Incorporating target heterogeneity in drug designJournal of Cellular Biochemistry, 2001
- Resistance to HIV Protease Inhibitors: A Comparison of Enzyme Inhibition and Antiviral PotencyBiochemistry, 1998
- Molecular Basis of Resistance to HIV-1 Protease Inhibition: A Plausible HypothesisBiochemistry, 1998
- Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 ProteaseJournal of Medicinal Chemistry, 1997
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzymeJournal of the American Chemical Society, 1995
- L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease InhibitorJournal of Medicinal Chemistry, 1994
- Rational Design of Peptide-Based HIV Proteinase InhibitorsScience, 1990